NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

Elvisdk

I’m very sorry to hear about your wife, and I know the despair that you are both feeling. I’m sending my positive thoughts and hope to you and your family.

I don’t think it’s possible to get DCVax treatment at this time, but there is another promising personalized cell immunotherapy called TIL (tumor infiltrating lymphocytes) for solid tumors that is recruiting for a clinical trial for non-small cell lung cancer (NSCLC). Not sure where you live, but there’s several locations across the country. It does require a tumor sample to make the treatment, so I’m not sure if it’s possible in your wife’s case.

Some information about this trial here: https://www.iovance.com/clinical/iov-lun-202-non-small-cell-lung-cancer/

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL) (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC)
 
Immunotherapy For Metastatic Non-Small Cell Lung Cancer (NSCLC)

TUMOR INFILTRATING LYMPHOCYTE (TIL) therapy is derived from a patient’s own immune cells called lymphocytes that have come to the site of tumor to kill the tumor.

The TIL therapy under investigation in this clinical trial, LN-145, is expanded and rejuvenated TIL that was extracted from the patient’s own tumor.

ADDITIONAL INFORMATION ABOUT TIL:

* Data from multiple academic center trials in non-small cell lung cancer (NSCLC) show a positive association between the presence of TIL in NSCLC tumors and patient outcomes. A clinical study run by H. Lee Moffitt Cancer Center showed durable complete responses with Moffitt’s TIL in patients with NSCLC who progressed on nivolumab treatment.1,2

* For more information about clinical results with TIL therapies, please visit our Publication And Scientific Presentations page here.

* To learn more about TIL, please visit our Iovance TIL technology page here.

CLINICAL TRIAL OVERVIEW

IOV-LUN-202 is a Phase 2 clinical trial of Iovance TIL therapy (LN-145), enrolling patients that have been diagnosed with histologically confirmed recurrent or metastatic non-small cell lung cancer (NSCLC) across the following four cohorts:

* Cohort 1: NSCLC patients whose tumors do not express PD-L1, are without a known driver mutation, who have received a single line of approved systemic therapy (combined checkpoint inhibitor (CPI) + chemotherapy ± bevacizumab). Patients must meet study requirements for tumor resection.

* Cohort 2: NSCLC patients whose tumors express PD-L1, are without a known driver mutation, who have received a single line of approved systemic therapy (CPI + chemotherapy ± bevacizumab). Patients must meet study requirements for tumor resection.

* Cohort 3: NSCLC patients whose tumors do not express PD-L1, are without a known driver mutation, who have received a single line of approved systemic therapy (CPI + chemotherapy ± bevacizumab). Patients should not meet study requirements for surgical tumor resection and their TIL will be grown from a tumor biopsy sample instead.

* Cohort 4: LN-145 retreatment in patients who were previously treated in Cohorts 1-3.

YOU MAY QUALIFY FOR THE TRIAL IF:
* You have been diagnosed histologically with locally advanced or metastatic NSCLC
* You are at least 18 years old
* You have documented PD-L1 expression status
* You have received a single line of systemic therapy that included CPI and chemotherapy, with a minimum washout period of 21 days
* You meet specified lab parameters
* You meet the requirements for having a resectable lesion (or aggregate lesions) or qualify for tumor harvest via core biopsy
 
If you satisfy these key eligibility criteria, you may be eligible to participate in this clinical trial. There are other additional eligibility criteria that can only be assessed by a trial physician.
To learn more about the trial, please call: 1-866-565-4410


Here’s the trial information:

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

https://www.clinicaltrials.gov/ct2/show/NCT04614103

Detailed Description:
LN-145 is a ready-to-infuse, autologous TIL therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI and further optimized by Iovance for the treatment of patients with metastatic NSCLC. The cell transfer therapy used in this study involves patients receiving an NMA lymphocyte depleting preparative regimen, followed by infusion of autologous TIL, then finally followed by the administration of IL-2.


Locations

United States, California
City of Hope Recruiting
Duarte, California, United States, 91010

United States, Kentucky
University of Louisville Recruiting
Louisville, Kentucky, United States, 40202

United States, Michigan
Karmanos Cancer Institute Recruiting
Detroit, Michigan, United States, 48201

United States, New Jersey
MD Anderson Cooper Recruiting
Camden, New Jersey, United States, 08103

United States, Ohio
University of Cincinnati Medical Center Recruiting
Cincinnati, Ohio, United States, 45219

Sponsors and Collaborators
Iovance Biotherapeutics, Inc.


Iovance has another clinical trial for NSCLC in combination with various immune checkpoint inhibitors (Keytruda, or Opdivo, or Yervoy)

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

https://clinicaltrials.gov/ct2/show/NCT03645928?term=iovance&draw=4&rank=2


A recent article about the treatment:

This Big Leap in Cancer Treatment Could Change the Landscape
TIL therapy looks able to win a large addressable market, and Iovance is the leader of the pack.
Patrick Bafuma Apr 1, 2021 at 6:27AM

https://www.fool.com/investing/2021/04/01/this-big-leap-in-cancer-treatment-could-change-the/